Levels of oxidative stress to diagnosis and their association with the survival profile in patients with breast cancer operable in initial stages: a pilot study

Authors

  • Carolina Panis Unioeste
  • Luciana Sagan Batista de Souza
  • Daniel Rech
  • Aedra CB Kawassaki
  • Daniel Felipe Henriques Calistro da Silva
  • Jessica Malanoswski
  • Hellen dos Santos Jaques
  • Fernanda Mara Alves
  • Vitor T Maito
  • Bruno V Capestrini
  • Stefania Tagliari de Oliveira

DOI:

https://doi.org/10.48075/aes.v4i1.27415
Supporting Agencies
Fundação Araucária, Conselho Nacional de Desenvolvimento Tecnológico e Programa de Apoio à Pesquisa no SUS

Keywords:

oxidative stress, breast cancer, mortality

Abstract

High levels of oxidative stress have been associated with a worse prognosis of breast cancer, but its relationship is notknown as a possible predictor of survival. In this study we investigated the association between circulating levels of oxidative stress at the time of diagnosis and the survival profile of patients with operable breast tumors. A prospective study was conducted in a population of 606 female patients with early stage breast tumors between the years 2015-2020. Among these patients, 18 died during the study, being paired with 36 patients who remained alive during the study period. Blood samples were collected at diagnosis, and stress levels were quantified by measuring the nitric oxide (NO) metabolites and plasma lipid peroxidation profile. In the death group, a plasma lipoperoxidation profile and high NO levels at diagnosis were observed when compared to the group of living patients. High levels of plasma lipoperoxidation were directly related to the development of metastases in the group of living patients. The results suggest that the increased systemic oxidative profile at the diagnosis observed in patients with breast cancer is directly related to the outcome of death in 5 years.

References

Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York, Oxford University, 4th edition, 2007.

Pani G, Giannoni E, Galeotti T, Chiarugi P. Redox-based escape mechanism from death: the cancer lesson. Antiox Redox Signal 11(11): 2791-2802, 2009.

Panis, C., Victorino, V. J., Herrera, A. C., Cecchini, A. L., Simão, A. N., Tomita, L. Y., & Cecchini, R. Can Breast Tumors Affect the Oxidative Status of the Surrounding Environment? A Comparative Analysis among Cancerous Breast, Mammary Adjacent Tissue, and Plasma. Oxid Med Cell Longev. 2015;2015:6429812.

Shaw PG, Chaerkady R, Wang T, Vasilatos S, Huang Y, van Houten B, Pandey A, Davidson NE. Integrated proteomic and metabolic analysis of breast cancer progression. PLoS ONE 8(9): e76220, 2013.

Mencalha A, Victorino VJ, Cecchini R, Panis C. Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics. Anticancer Res 34: 1127-1140, 2014.

Gauthier N, Arnould L, Chantôme A, Reisser D, Bettaieb A, Reveneau S, Jeannin JF. To stimulate or to inhibit nitric oxide production in mammary tumors? Bull Cancer 91(9): 705-712, 2004.

Fang J, Nakamura H, Iyer AK. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15(7-8): 475-486, 2007.

Pires BRB, Panis C, Alves VD, Herrera ACSA, Binato R, Pizzatti L, Cecchini R, Abdelhay E. Label-Free Proteomics Revealed Oxidative Stress and Inflammation as Factors That Enhance Chemoresistance in Luminal Breast Cancer. Oxid Med Cell Longev. 2019;2019:5357649.

de Sa Junior PL, Camara DAD, Porcacchia AS, Fonseca PMM, Jorge SD, Araldi RP, Ferreira AK. The roles of ROS in cancer heterogeneity and therapy. Oxid Med Cell Longev. 2017;2017:2467940.

Herrera AC, Victorino VJ, Campos FC, Verenitach BD, Lemos LT, Aranome AM, Oliveira SR, Cecchini AL, Simão AN, Abdelhay E, Panis C, Cecchini R. Impact of tumor removal on the systemic oxidative profile of patients with breast cancer discloses lipid peroxidation at diagnosis as a putative marker of disease recurrence. Clin Breast Cancer. 2014;14:451–9.

Lemos LG, Victorino VJ, Herrera AC, Aranome AM, Cecchini AL, Simão AN, Panis C, Cecchini R. Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer. Int Immunopharmacol. 2015 Jul;27(1):8-14.

Victorino VJ, Campos FC, Herrera AC, Colado Simão AN, Cecchini AL, Panis C, Cecchini R. Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumour Biol. 2014 Apr;35(4):3025-34.

Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, Simão AN, Barbosa DS, Pinge-Filho P, Cecchini R, Cecchini AL. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. 2012 Jun;133(3):881-8.

Sedlak, J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal. Biochem 1968, 25: 192-205.

Gonzales-Flecha B, Lleswy S, Boveris A. Hydroperoxide-initiated chemiluminescence: An assay for oxidative stress in biopsies of heart, liver and muscle. Free Rad Biol Med 1991, 10: 93-100.

Okon IS, Zou MH. Mitochondrial ROS and cancer drug resistance: Implications for therapy. Pharmacol Res. 2015;100:170-174.

Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel). 2010;2(2):859-884.

Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006 May 11;5:14.

Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 2015;16(1):32-43.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564.

Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006 Mar 1;66(5):2725-31.

Muñoz-Nájar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 2006 Apr 13;25(16):2379-92.

Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74.

Dutra MC, Rezende MA, Andrade VP, Soares FA, Ribeiro MV, Paula EC, & Gobbi H. Imunofenótipo e evolução do câncer de mama: comparação entre mulheres muito jovens e mulheres na pós-menopausa. Rev Bras Ginecol e Obstet. 2009; 31(2):54-60

Sundquist M, Thorstenson S, Brudin L, Wingren S, Nordenskjöld B. Incidence and prognosis in early onset breast cancer. Breast. 2002; 11(1):30-5.

Chan A, Pintilie M, Vallis K, Girourd C, Goss P. Breast cancer in women < or = 35 years: review of 1002 cases from a single institution. Ann Oncol. 2000; 11(10):1255-62.

Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med. 2015;66(1):281–296.

Kang C, LeRoith D, Gallagher EJ. Diabetes, Obesity, and Breast Cancer. Endocrinology. 2018;159(11):3801-3812.

Published

11-06-2021

How to Cite

PANIS, C.; SAGAN BATISTA DE SOUZA, L.; RECH, D.; KAWASSAKI, A. C.; CALISTRO DA SILVA, D. F. H.; MALANOSWSKI, J.; JAQUES, H. dos S.; ALVES, F. M.; MAITO, V. T.; CAPESTRINI, B. V.; DE OLIVEIRA, S. T. Levels of oxidative stress to diagnosis and their association with the survival profile in patients with breast cancer operable in initial stages: a pilot study. Acta Elit Salutis, [S. l.], v. 4, n. 1, 2021. DOI: 10.48075/aes.v4i1.27415. Disponível em: https://e-revista.unioeste.br/index.php/salutis/article/view/27415. Acesso em: 17 jul. 2024.

Issue

Section

Artigos Originais